

Dupilumab effective in atopic dermatitis

October 4 2016



(HealthDay)—Dupilumab is effective for patients with moderate-to-severe atopic dermatitis that is inadequately controlled by topical treatment, according to a study published online Oct. 1 in the *New*

England Journal of Medicine. The research was published to coincide with the annual European Academy of Dermatology and Venereology Congress, held from Sept. 28 to Oct. 2 in Vienna.

Eric L. Simpson, M.D., from the Oregon Health and Science University in Portland, and colleagues conducted two randomized phase 3 trials (SOLO 1: 671 [patients](#) and SOLO 2: 708 patients) involving adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatment. Patients were randomized to receive subcutaneous dupilumab or placebo weekly, or dupilumab every other week alternating with placebo.

The researchers found that the primary outcome (proportion of patients who had a score of 0 or 1 on the Investigator's Global Assessment and a reduction of two points or more on that score from baseline at week 16) occurred in 38, 37, and 10 percent of those receiving dupilumab every other week, dupilumab every week, and placebo, respectively (both P < 0.001). "Results from larger studies of longer duration are needed to assess the effectiveness and safety of long-term treatment with dupilumab," the authors write.

The study was funded by Sanofi and Regeneron Pharmaceuticals, the manufacturers of dupilumab.

More information: [Abstract](#)
[Full Text](#)
[More Information](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Dupilumab effective in atopic dermatitis (2016, October 4) retrieved 2 February 2023 from <https://medicalxpress.com/news/2016-10-dupilumab-effective-atopic-dermatitis.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.